Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T18:37:22.179Z.
Calculation as of: 2026-10-06T18:37:22.179Z.
Quote observation: 2026-10-06T18:35:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1bbfd340dc97f0e27695e9fb41fa93114c5667a27bee763cb432d33a5513a7eb
PEG RATIO
N/A
Standard BioTools Inc.
Market Cap
$286.16M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Standard BioTools Inc. (LAB) | $286.16M | N/A |
| Abeona Therapeutics Inc. (ABEO)vs › | $285.83M | N/A |
| Sagimet Biosciences Inc. (SGMT)vs › | $286.55M | N/A |
| Indaptus Therapeutics, Inc. (INDP)vs › | $287.63M | N/A |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $284.04M | N/A |
| Aurora Cannabis Inc. (ACB)vs › | $282.46M | N/A |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $281.92M | N/A |
| Larimar Therapeutics, Inc. (LRMR)vs › | $292.96M | N/A |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $271.89M | N/A |
| Scribe Therapeutics Inc. (SCTX)vs › | $272.99M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
